User menu

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

Bibliographic reference Cipponi, Arcadi ; Wieers, Grégoire ; van Baren, Nicolas ; Coulie, Pierre. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. In: Cancer Immunology Immunotherapy, Vol. 60, no. 8, p. 1153-60 (2011)
Permanent URL http://hdl.handle.net/2078.1/124091
  1. Mantovani Alberto, Allavena Paola, Sica Antonio, Balkwill Frances, Cancer-related inflammation, 10.1038/nature07205
  2. Hérin M., Lemoine C., Weynants P., Vessière F., Van Pel A., Boon T., Knuth A., Devos R., Production of stable cytolytic T-cell clones directed against autologous human melanoma, 10.1002/ijc.2910390320
  3. Muul LM, Spiess PJ, Director EP, Rosenberg SA (1987) Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989–995
  4. Rosenberg Steven A., Packard Beverly S., Aebersold Paul M., Solomon Diane, Topalian Suzanne L., Toy Stephen T., Simon Paul, Lotze Michael T., Yang James C., Seipp Claudia A., Simpson Colleen, Carter Charles, Bock Steven, Schwartzentruber Douglas, Wei John P., White Donald E., Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma, 10.1056/nejm198812223192527
  5. Rosenberg S. A., Progress in the development of immunotherapy for the treatment of patients with cancer, 10.1046/j.1365-2796.2001.00911.x
  6. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, 10.1126/science.1840703
  7. Gajewski Thomas F., Louahed Jamila, Brichard Vincent G., Gene Signature in Melanoma Associated With Clinical Activity : A Potential Clue to Unlock Cancer Immunotherapy, 10.1097/ppo.0b013e3181eacbd8
  8. Louahed J, Gruselle O, Gaulis S, Coche T, Eggermont AM, Kruit W, Dréno B, Chiarion Sileni V, Lehmann F, Brichard VG (2008) Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032–18031). J Clin Oncol 26:9045
  9. Gajewski T, Zha Y, Thurner B, Schuler G (2009) Association of gene expression profile in metastatic melanoma and survival to a dendritic cell-based vaccine. J Clin Oncol 27:9002
  10. Oble DA, Loewe R, Yu P, Mihm MC Jr (2009) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun 9:3
  11. Larsen TE, Grude TH (1978) A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 3. The relation between the tumour-associated lymphocyte infiltration and age and sex, tumour cell type, pigmentation, cellular atypia, mitotic count, depth of invasion, ulceration, tumour type and prognosis. Acta Pathol Microbiol Scand A 86A:523–530
  12. Johnson O. Kenneth, Emrich Lawrence J., Karakousis Constantine P., Rao Uma, Greco William R., Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical stage I, 10.1002/1097-0142(19850301)55:5<1107::aid-cncr2820550528>3.0.co;2-c
  13. Clark W. H., Elder D. E., Guerry D., Braitman L. E., Trock B. J., Schultz D., Synnestvedt M., Halpern A. C., Model Predicting Survival in Stage I Melanoma Based on Tumor Progression, 10.1093/jnci/81.24.1893
  14. Clemente Claudio G., Mihm Martin C., Bufalino Rosaria, Zurrida Stefano, Collini Paola, Cascinelli Natale, Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, 10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5
  15. Tuthill Ralph J., Unger Joseph M., Liu P.Y., Flaherty Lawrence E., Sondak Vernon K., Risk Assessment in Localized Primary Cutaneous Melanoma : A Southwest Oncology Group Study Evaluating Nine Factors and a Test of the Clark Logistic Regression Prediction Model, 10.1309/wbf7-n8kh-71kt-rvq9
  16. Mandalà M., Imberti G.L., Piazzalunga D., Belfiglio M., Labianca R., Barberis M., Marchesi L., Poletti P., Bonomi L., Novellino L., Di Biagio K., Milesi A., Guerra U., Tondini C., Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database, 10.1016/j.ejca.2009.05.034
  17. Barnhill Raymond L., Fine Judith A., Roush George C., Berwick Marianne, Predicting five-year outcome for patients with cutaneous melanoma in a population-based study, 10.1002/(sici)1097-0142(19960801)78:3<427::aid-cncr8>3.0.co;2-g
  18. Taylor Rebecca C., Patel Ami, Panageas Katherine S., Busam Klaus J., Brady Mary S., Tumor-Infiltrating Lymphocytes Predict Sentinel Lymph Node Positivity in Patients With Cutaneous Melanoma, 10.1200/jco.2006.08.9755
  19. Burton AL, Roach BA, Mays MP, Chen AF, Ginter BA, Vierling AM, Scoggins CR, Martin RC, Stromberg AJ, Hagendoorn L, McMasters KM (2011) Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg 77:188–192
  20. Balch Charles M., Gershenwald Jeffrey E., Soong Seng-jaw, Thompson John F., Atkins Michael B., Byrd David R., Buzaid Antonio C., Cochran Alistair J., Coit Daniel G., Ding Shouluan, Eggermont Alexander M., Flaherty Keith T., Gimotty Phyllis A., Kirkwood John M., McMasters Kelly M., Mihm Martin C., Morton Donald L., Ross Merrick I., Sober Arthur J., Sondak Vernon K., Final Version of 2009 AJCC Melanoma Staging and Classification, 10.1200/jco.2009.23.4799
  21. Mihm MC Jr, Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 74:43–47
  22. Bogunovic D., O'Neill D. W., Belitskaya-Levy I., Vacic V., Yu Y.-L., Adams S., Darvishian F., Berman R., Shapiro R., Pavlick A. C., Lonardi S., Zavadil J., Osman I., Bhardwaj N., Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival, 10.1073/pnas.0905139106
  23. Ropponen Kirsi M., Eskelinen Matti J., Lipponen Pertti K., Alhava Esko, Kosma Veli-Matti, Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer, 10.1002/(sici)1096-9896(199707)182:3<318::aid-path862>3.0.co;2-6
  24. Pagès Franck, Berger Anne, Camus Matthieu, Sanchez-Cabo Fatima, Costes Anne, Molidor Robert, Mlecnik Bernhard, Kirilovsky Amos, Nilsson Malin, Damotte Diane, Meatchi Tchao, Bruneval Patrick, Cugnenc Paul-Henri, Trajanoski Zlatko, Fridman Wolf-Herman, Galon Jérôme, Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, 10.1056/nejmoa051424
  25. Galon J., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, 10.1126/science.1129139
  26. Zhang Lin, Conejo-Garcia Jose R., Katsaros Dionyssios, Gimotty Phyllis A., Massobrio Marco, Regnani Giorgia, Makrigiannakis Antonis, Gray Heidi, Schlienger Katia, Liebman Michael N., Rubin Stephen C., Coukos George, Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer, 10.1056/nejmoa020177
  27. Ferradini L, Mackensen A, Genevée C, Bosq J, Duvillard P, Avril M F, Hercend T, Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion., 10.1172/jci116278
  28. Mackensen A, Carcelain G, Viel S, Raynal M C, Michalaki H, Triebel F, Bosq J, Hercend T, Direct evidence to support the immunosurveillance concept in a human regressive melanoma., 10.1172/jci117116
  29. Zorn Emmanuel, Hercend Thierry, A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation, 10.1002/(sici)1521-4141(199902)29:02<592::aid-immu592>3.0.co;2-2
  30. Zorn Emmanuel, Hercend Thierry, A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion, 10.1002/(sici)1521-4141(199902)29:02<602::aid-immu602>3.0.co;2-y
  31. Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Lienard D, Speiser D, Dunbar R, Cerundolo V, Cerottini JC, Romero P (1999) Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368–376. Cancer Res 59:4050–4055
  32. Anichini Andrea, Molla Alessandra, Mortarini Roberta, Tragni Gabrina, Bersani Ilaria, Di Nicola Massimo, Gianni Alessandro M., Pilotti Silvana, Dunbar Rod, Cerundolo Vincenzo, Parmiani Giorgio, An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions, 10.1084/jem.190.5.651
  33. Valmori D., Dutoit V., Lienard D., Lejeune F., Speiser D., Rimoldi D., Cerundolo V., Dietrich P.-Y., Cerottini J.-C., Romero P., Tetramer-Guided Analysis of TCR  -Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients, 10.4049/jimmunol.165.1.533
  34. Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini J-C, Romero P (2000) Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60:4499–4506
  35. Haanen J. B. A. G., Baars A., Gomez R., Weder P., Smits M., de Gruijl T. D., von Blomberg B. M. E., Bloemena E., Scheper R. J., van Ham S. M., Pinedo H. M., van den Eertwegh A. J. M., Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients, 10.1007/s00262-005-0018-5
  36. Lurquin Christophe, Lethé Bernard, De Plaen Etienne, Corbière Véronique, Théate Ivan, van Baren Nicolas, Coulie Pierre G., Boon Thierry, Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, 10.1084/jem.20041378
  37. Rosenberg S. A., Dudley M. E., Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes, 10.1073/pnas.0405730101
  38. Goff Stephanie L., Smith Franz O., Klapper Jacob A., Sherry Richard, Wunderlich John R., Steinberg Seth M., White Donald, Rosenberg Steven A., Dudley Mark E., Yang James C., Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL : , 10.1097/cji.0b013e3181f05b91
  39. Strohal R, Paucz L, Pehamberger H, Stingl G (1994) T-cell receptor repertoire of lymphocytes infiltrating cutaneous melanoma is predominated by V alpha specificities present in T-cells of normal human skin. Cancer Res 54:4734–4739
  40. Clemente C, Rao S, Lupetti R, Tragni G, Pisarra P, Bersani I, Parmiani G, Mihm MC Jr, Sensi M (1998) Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma. Lab Invest 78:619–627
  41. Yazdi Amir S., Morstedt Kathrin, Puchta Ursula, Ghoreschi Kamran, Flaig Michael J., Rocken Martin, Sander Christian A., Heterogeneity of T-Cell Clones Infiltrating Primary Malignant Melanomas, 10.1038/sj.jid.5700082
  42. thor Straten P, Becker J C, Seremet T, Bröcker E B, Zeuthen J, Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma., 10.1172/jci118790
  43. Hishii M., Andrews D., Boyle L. A., Wong J. T., Pandolfi F., van den Elsen P. J., Kurnick J. T., In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites, 10.1073/pnas.94.4.1378
  44. Ladanyi A., T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma, 10.1158/1078-0432.ccr-1161-03
  45. Anichini A., Molla A., Vegetti C., Bersani I., Zappasodi R., Arienti F., Ravagnani F., Maurichi A., Patuzzo R., Santinami M., Pircher H., Di Nicola M., Mortarini R., Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma, 10.1158/0008-5472.can-10-2028
  46. Ohnmacht Galen A., Marincola Francesco M., Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma, 10.1002/(sici)1097-4652(200003)182:3<332::aid-jcp3>3.0.co;2-z
  47. Garcia-Lora Angel, Algarra Ignacio, Garrido Federico, MHC class I antigens, immune surveillance, and tumor immune escape, 10.1002/jcp.10290
  48. Coulie Pierre G., Somville Michel, Lehmann Frédéric, Hainaut Philippe, Brasseur Francis, Devos René, Boon Thierry, Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells, 10.1002/ijc.2910500220
  49. Germeau Catherine, Ma Wenbin, Schiavetti Francesca, Lurquin Christophe, Henry Emmanuelle, Vigneron Nathalie, Brasseur Francis, Lethé Bernard, De Plaen Etienne, Velu Thierry, Boon Thierry, Coulie Pierre G., High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, 10.1084/jem.20041379
  50. Weishaupt C., Munoz K. N., Buzney E., Kupper T. S., Fuhlbrigge R. C., T-Cell Distribution and Adhesion Receptor Expression in Metastatic Melanoma, 10.1158/1078-0432.ccr-06-2450
  51. Harlin H., Meng Y., Peterson A. C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T. F., Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment, 10.1158/0008-5472.can-08-2281
  52. Corbière Véronique, Chapiro Jacques, Stroobant Vincent, Ma Wenbin, Lurquin Christophe, Lethé Bernard, van Baren Nicolas, Van den Eynde Benoît J., Boon Thierry, Coulie Pierre G., Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases, 10.1158/0008-5472.can-10-2693
  53. Zippelius A., Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance, 10.1158/0008-5472.can-03-3066
  54. Vazquez-Cintron E. J., Monu N. R., Frey A. B., Tumor-Induced Disruption of Proximal TCR-Mediated Signal Transduction in Tumor-Infiltrating CD8+ Lymphocytes Inactivates Antitumor Effector Phase, 10.4049/jimmunol.1001157
  55. Monu N., Frey A. B., Suppression of Proximal T Cell Receptor Signaling and Lytic Function in CD8+ Tumor-Infiltrating T Cells, 10.1158/0008-5472.can-07-1441
  56. Gajewski Thomas F., Meng Yuru, Blank Christian, Brown Ian, Kacha Aalok, Kline Justin, Harlin Helena, Immune resistance orchestrated by the tumor microenvironment, 10.1111/j.1600-065x.2006.00442.x
  57. Demotte Nathalie, Stroobant Vincent, Courtoy Pierre J., Van Der Smissen Patrick, Colau Didier, Luescher Immanuel F., Hivroz Claire, Nicaise Julie, Squifflet Jean-Luc, Mourad Michel, Godelaine Danièle, Boon Thierry, van der Bruggen Pierre, Restoring the Association of the T Cell Receptor with CD8 Reverses Anergy in Human Tumor-Infiltrating Lymphocytes, 10.1016/j.immuni.2008.01.011
  58. Hodi F. Stephen, O'Day Steven J., McDermott David F., Weber Robert W., Sosman Jeffrey A., Haanen John B., Gonzalez Rene, Robert Caroline, Schadendorf Dirk, Hassel Jessica C., Akerley Wallace, van den Eertwegh Alfons J.M., Lutzky Jose, Lorigan Paul, Vaubel Julia M., Linette Gerald P., Hogg David, Ottensmeier Christian H., Lebbé Celeste, Peschel Christian, Quirt Ian, Clark Joseph I., Wolchok Jedd D., Weber Jeffrey S., Tian Jason, Yellin Michael J., Nichol Geoffrey M., Hoos Axel, Urba Walter J., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, 10.1056/nejmoa1003466
  59. Brahmer Julie R., Drake Charles G., Wollner Ira, Powderly John D., Picus Joel, Sharfman William H., Stankevich Elizabeth, Pons Alice, Salay Theresa M., McMiller Tracee L., Gilson Marta M., Wang Changyu, Selby Mark, Taube Janis M., Anders Robert, Chen Lieping, Korman Alan J., Pardoll Drew M., Lowy Israel, Topalian Suzanne L., Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, 10.1200/jco.2009.26.7609
  60. Uyttenhove Catherine, Pilotte Luc, Théate Ivan, Stroobant Vincent, Colau Didier, Parmentier Nicolas, Boon Thierry, Van den Eynde Benoît J, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, 10.1038/nm934
  61. Wilke CM, Wu K, Zhao E, Wang G, Zou W (2010) Prognostic significance of regulatory T cells in tumor. Int J Cancer 127:748–758
  62. Ahmadzadeh M., Felipe-Silva A., Heemskerk B., Powell D. J., Wunderlich J. R., Merino M. J., Rosenberg S. A., FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions, 10.1182/blood-2008-06-163048
  63. Wang Helen Y, Lee Dean A, Peng Guangyong, Guo Zhong, Li Yanchun, Kiniwa Yukiko, Shevach Ethan M, Wang Rong-Fu, Tumor-Specific Human CD4+ Regulatory T Cells and Their Ligands, 10.1016/s1074-7613(03)00359-5
  64. Wang H. Y., Peng G., Guo Z., Shevach E. M., Wang R.-F., Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells, 10.4049/jimmunol.174.5.2661
  65. Francois V., Ottaviani S., Renkvist N., Stockis J., Schuler G., Thielemans K., Colau D., Marchand M., Boon T., Lucas S., van der Bruggen P., The CD4+ T-Cell Response of Melanoma Patients to a MAGE-A3 Peptide Vaccine Involves Potential Regulatory T Cells, 10.1158/0008-5472.can-08-3726
  66. Baron Udo, Floess Stefan, Wieczorek Georg, Baumann Katrin, Grützkau Andreas, Dong Jun, Thiel Andreas, Boeld Tina J., Hoffmann Petra, Edinger Matthias, Türbachova Ivana, Hamann Alf, Olek Sven, Huehn Jochen, DNA demethylation in the humanFOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells, 10.1002/eji.200737594
  67. Boon Thierry, Coulie Pierre G., Eynde Benoît J. Van den, Bruggen Pierre van der, HUMAN T CELL RESPONSES AGAINST MELANOMA, 10.1146/annurev.immunol.24.021605.090733